Brief: Hyphens Pharma International Says Unit Entered Exclusive License, Supply Deal
March 12 (Reuters) - Hyphens Pharma International Ltd
HYPH.SI :
* UNIT ENTERED EXCLUSIVE LICENSE, SUPPLY AND
COMMERCIALISATION
DEAL WITH MC2 THERAPEUTICS
* WYNZORA CREAM APPROVED FOR UNITED STATES AND COUNTRIES IN
EUROPE
* UNDER DEAL, GROUP WILL PAY MC2 TOTAL EUR 2.5 MILLION
* DEAL FOR EXCLUSIVE RIGHTS TO REGISTER AND COMMERCIALISE
WYNZORA
CREAM
Further company coverage: HYPH.SI
Recent news on Hyphens Pharma International
See all newsSingapore's Hyphens Pharma half-year profit jumps as margins improve
Brief: Hyphens Pharma International Updates On Cerapro® Med Skin Barrier Cream
Brief: Hyphens Pharma International Says Unit Gets Exclusive Rights To Commercialise Metoject
Brief: Hyphens Pharma International Posts FY Net Income Of SGD 10.9 Million
Brief: Hyphens Pharma International Licenses Amenalief From Maruho For ASEAN